Evidence map›Paper›PMID 31328876›Full record

Trial reportJournal of clinical hypertension (Greenwich, Conn.)2019

Angiotensin II receptor blocker attenuates stress pressor response in young adult African Americans.

Jin Hee Jeong, Coral Hanevold, Ryan A Harris, Gaston Kapuku, Jennifer Pollock, David Pollock, Gregory Harshfield

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jin Hee JeongDepartment of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.ORCID 0000-0002-8748-8429
Coral HanevoldDepartment of Pediatrics, Division of Nephrology, University of Washington, Seattle, Washington.
Ryan A HarrisDepartment of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.
Gaston KapukuDepartment of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.
Jennifer PollockDepartment of Medicine, University of Alabama, Birmingham, Alabama.
David PollockDepartment of Medicine, University of Alabama, Birmingham, Alabama.
Gregory HarshfieldDepartment of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.
Augusta University · USUniversity of Alabama at Birmingham · USUniversity of Washington · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Vascular and renal responses to stressP01HL069999 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI GEORGE, VARGHESE · 2002 to 2018
$31.1M
NHLBI NIH HHS P01 HL069999NIH HHS P51 OD011132
6 · The paper itself

Abstract

African Americans (AAs) are susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular (CV) outcomes. Psychological stress is proposed to contribute to the development of HTN; however, the potential role of the renin-angiotensin system (RAS) in stress-related HTN in AAs is largely unknown. In this study, we tested the hypothesis that activation of RAS is a potential contributing factor for altered CV responses to stress, and suppression of angiotensin II (Ang II) activity will improve hemodynamic responses to a prolonged mental stressor in healthy young AAs. Utilizing a double-blind, randomized, crossover study design, 132 normotensive AAs (25 ± 7 years) were treated with either a placebo (PLC) or 150 mg/d irbesartan (an Ang II type 1 receptor blocker; ARB) for 1 week. On the final day of each treatment, hemodynamic measures and urinary sodium excretion (UNaV) were collected before, during and after a 45 minute-mental stress. The magnitude of stress-induced increase in blood pressure with ARB was blunted and delayed compared to PLC. Systolic blood pressure at the end of recovery on ARB was significantly lower compared to either PLC (110 ± 13 vs 117 ± 12 mm Hg respectively; P < 0.001) or the prestress level on ARB (P = 0.02). ARB treatment reduced overall vasoconstriction and improved poststress UNaV. ARB attenuated blood pressure responses to mental stress and improved the poststress BP recovery process which were partly linked to reduced overall vasoconstriction and improved stress-induced UNaV in young adult AAs prior to the development of disease conditions. These results suggest that treatment approaches that inhibit RAS action could have significant relevance to potentially lower susceptibility to stress responses and eventually the premature development of HTN in AAs.

Indexed as

AdolescentAdultAngiotensin Receptor AntagonistsBlack or African AmericanBlood PressureCase-Control StudiesCross-Over StudiesDouble-Blind MethodFemaleHemodynamicsHumansHypertensionIrbesartanMalePlacebosRenin-Angiotensin SystemAngiotensin Receptor AntagonistsIrbesartanPlacebosSodiumAfrican Americansangiotensin IIhypertensionstress

Identifiers

PMID31328876
PMCPMC6690765
OpenAlexW2963530295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.